Pharmaceuticals
Singapore mRNA vaccine developer raises $140m
RVAC Medicines, a Singapore-based company involved in developing messenger RNA (mRNA) vaccines for COVID-19, has closed a Series B round that takes its overall funding to USD 140m.
China digital CRO Elixir raises $52m
Elixir, a China-based clinical research organisation (CRO), has raised a USD 52m Series A round from Lyfe Capital, Chow Tai Fook Investment, and Sinovation Ventures.
China virotherapy specialist Binhui Biopharm raises $47m
Binhui Biopharm, a Chinese biotech firm specialising in oncolytic virus immune-oncology, has raised CNY 300m (USD 47m) in an extended Series B round led by Yangtze River Pharmaceutical Group.
China stem cell drug developer Baylx raises $47m
Baylx, a Beijing-based drug developer that utilises stem cell technology, has raised CNY 300m （USD 47m）across two rounds - a Series B and a Series B extension.
China's METiS Pharmaceuticals raises $150m
METiS Pharmaceuticals, a Hangzhou-based drug formulation company has raised USD 150m through two funding rounds led by PICC Capital and China Life PE.
CDH, Huaxing lead $120m Series B for China’s InnoRNA
CDH Investments and Huaxing Healthcare Fund have led a USD 120m Series B for InnoRNA, a China-based mRNA drug developer. Existing investors CPE and Fangyuan Capital re-upped.
CBC strikes China's first royalty-based biomedicine deal
R-Bridge Fund, a credit vehicle established by healthcare-focused private equity firm CBC Group, has completed what it claims is the first royalty-backed investment in China’s biomedicine space.
Deal focus: Medilink chases global ADC opportunity
The Medilink Therapeutics team spun out from Kelun-Biotech to develop antibody drug conjugates capable of competing with the world’s best. Its USD 70m Series B will support the pursuit of this goal
Genesis leads Series A extension for China's Nutshell Therapeutics
Nutshell Therapeutics, a China-based specialist in protein-focused drugs, has raised USD 40m in an extended Series A led by Genesis Capital.
Lyfe, Qiming lead Series B for China ADC player Medilink
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised a USD 70m Series B led by Lyfe Capital and Qiming Venture Partners.
China cancer drug developer InxMed raises $50m
InxMed, a China-based biotech company focused on oncology treatments, has raised a USD 50m Series B round led by SDIC China Merchants Investment.
China 3D cell culture business secures Series B
CytoNiche, a Beijing-based provider of 3D micro-structure engineering technology used for stem cell research, has raised nearly CNY 300m (USD 47m) in a Series B led by Gaorong Capital and CICC Capital.
Q&A: Sylvan Group’s Gerald Leong
Gerald Leong, a 25-year veteran of Asian private equity, believes returns-focused impact investment is the future of the industry. His new firm, Singapore-based Sylvan Group, will attempt to prove it
Korea's Biorchestra gets $45m Series C
Biorchestra, a Korea-based drug developer specialising in RNA therapeutics for neurodegenerative diseases, has closed a Series C funding round of KRW 54bn (USD 45m).
AVCJ Awards 2021: Deal of the Year – Large Cap: China Biologic
For Centurium Capital, China Biologic was no ordinary take-private. It was the culmination of a multi-year effort to tighten the company’s shareholding structure and root out management inefficiencies
Singapore's Sylvan buys four local healthcare companies
Sylvan Group, a Singaporean private equity firm set up by Hyundai scion Kyungsun Chung, has acquired majority stakes in four local healthcare companies for USD 140.5m. These represent its first investments.
River Head Capital hits first close on latest reminbi fund
China’s River Head Capital has achieved a first close on its second Innovation Growth Fund, a renminbi-denominated vehicle that has an overall target of CNY 2bn (USD 135m).
TPG-owned clinical trials player raises new equity, debt
Novotech, an Asia-based clinical trials specialist controlled by TPG Capital, has secured USD 760m in new equity and debt financing at a post-deal valuation of approximately USD 3bn.
Goldman, Sofina lead Series C for China CDMO Zhenge
Goldman Sachs Asset Management and Sofina have led a USD 100m Series C round for Zhenge Biotech, a Shanghai-based contract development and manufacturing organisation (CDMO).
China gene therapy start-up Cure Genetics raises $60m
Advantech Capital has led a USD 60m Series B for Suzhou-based biotech player Cure Genetics. Other investors include Oriza Holdings, Blue Ocean Private Equity, and Qiming Venture Partners.
AGIC exits healthcare business Ritedose to Novo Holdings
AGIC Capital, which specializes in cross-border deals along the China-Europe axis, has agreed to sell pharmaceutical manufacturing and packaging business Ritedose Corporation to Novo Holdings.
China CDMO Thousand Oaks raises $240m
Thousand Oaks Biopharmaceuticals, a China-based contract development and manufacturing organization (CDMO), has raised CNY 1.5bn (USD 240m) in funding led by Goldstone Investment - a private equity unit of CITIC Securities - and CDH Investments.
China biotech player GenFleet raises $75m
GenFleet Therapeutics, a Chinese biotech developer focused on oncology and immunology, has secured a USD 75m Series C round led by Huagai Capital.
Blackbird backs Australia 3D cell culture platform
Australia’s Blackbird Ventures has led a $25 million Series B round for Inventia Life Science, a local start-up that provides 3D cell cultures for research and clinical purposes.